EA-230 is under clinical development by Exponential Biotherapies and currently in Phase II for Acute Inflammation. According to GlobalData, Phase II drugs for Acute Inflammation does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EA-230 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EA-230 overview
EA-230 is under development for the treatment of postoperative complications, radiation toxicity, acute systemic inflammation, sepsis and unspecified indications (other indications). It is administered as an infusion through intravenous route. The drug candidate is a small peptide immunoregulator.
It was also under development for the treatment of renal failure following major on-pump cardiac surgery.
Exponential Biotherapies overview
Exponential Biotherapies (EBI) is a innovative biopharmaceutical company that provides pharmaceutical services. It focuses on the discovery and development of novel small molecule drugs to treat a wide range of inflammatory disorders such as acute kidney injury, septic shock, radiation sickness, Anthrax and avian influenza infections. The company’s pipeline products include EA-230, a derivative of the human pregnancy hormone. EBI is headquartered at McLean in Den Haag, the Netherlands.
For a complete picture of EA-230’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
